Shares of Otonomy Inc. (OTIC) were down more than 18% in extended trading on Thursday after the company announced that its phase IIb trial of OTO-104 in patients with unilateral M‚niŠre’s disease narrowly missed achieving statistical significance.
Forex – financial instrument.Forex news
Shares of Otonomy Inc. (OTIC) were down more than 18% in extended trading on Thursday after the company announced that its phase IIb trial of OTO-104 in patients with unilateral M‚niŠre’s disease narrowly missed achieving statistical significance.